On March 27, 2024, Boundless Bio, a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares were offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. Boundless Bio’s common stock began trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD," and closed on April 2, 2024. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

The Wilson Sonsini team that advised Boundless Bio on intellectual property matters related to the IPO includes Mike Hostetler, Deborah Smith, Lauren Hodnett, Céline Bonnefous, and Jennifer Floyd.

For more information, please see Boundless Bio's press release. More coverage can be found at Fierce Biotech and BioSpace.